Claude Curran, MD
Psychiatry · Fall River, MANPI 1609980135
Payments from drug & device makers
Across 615 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Lundbeck LLC$821
- Sunovion Pharmaceuticals Inc.$556
- plus $2K from 16 others
What the payments were for
- Food & beverage$11,03699%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 226 | $3,911 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 96 | $2,006 |
| Otsuka America Pharmaceutical, Inc. | 42 | $1,155 |
| Alkermes, Inc. | 76 | $1,005 |
| Lundbeck LLC | 61 | $821 |
| Sunovion Pharmaceuticals Inc. | 32 | $556 |
| Vanda Pharmaceuticals Inc. | 22 | $522 |
| Teva Pharmaceuticals USA, Inc. | 14 | $207 |
| E.r. Squibb & Sons, L.L.C. | 4 | $174 |
| Orexo US, Inc. | 2 | $145 |
| Merck | 9 | $135 |
| Novartis | 7 | $118 |
| Johnson & Johnson | 4 | $65 |
| Corium, LLC | 6 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $37 |
| Indivior Inc. | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Neuronetics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$732
- VRAYLAR$375
- REXULTI$317
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- Fanapt$125
- Zubsolv$121
- COBENFY$108
How this compares
$11,116 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 87 | $133,059 |
| CaplytaLumateperone Tosylate | 54 | $92,763 |
| VraylarCariprazine Hcl | 41 | $68,576 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 573 | $49,304 |
| Alprazolam | 4,339 | $43,325 |
| VivitrolNaltrexone Microspheres | 23 | $40,159 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 92 | $36,151 |
| Risperdal ConstaRisperidone Microspheres | 18 | $25,754 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 943 | $25,071 |
| TrintellixVortioxetine Hydrobromide | 43 | $24,945 |
| Clonazepam | 2,505 | $20,151 |
| Gabapentin | 1,312 | $16,982 |
| Quetiapine Fumarate | 1,004 | $15,682 |
| Aripiprazole | 205 | $13,641 |
| Vilazodone Hcl | 131 | $12,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,155 | $133,05987 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,006 | $92,76354 claims |
| AbbVieVraylar, Viibryd | $3,911 | $72,58153 claims |
| Alkermes, Inc.Vivitrol | $1,005 | $40,15923 claims |
| Indivior Inc.Suboxone | $32 | $36,15192 claims |
| Johnson & JohnsonRisperdal Consta | $65 | $25,75418 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $37 | $24,94543 claims |
| Orexo US, Inc.Zubsolv | $145 | $10,41416 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $15 | $5,87813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in Fall River
- Lee CohenBoston$7M
- Dyanna DomiliciBoston$5.8M
- Arkadiy StolyarBelmont$3.3M
- Maurizio FavaBoston$2.8M
- Marc ShayAmesbury$1.7M
- Martha StarkNewton$1.6M
- Hadine JoffeBoston$1.5M
- Malini NairWinchester$1M
- Xiaoduo FanWorcester$950K
- Anthony RothschildWorcester$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.